Telix Agrees to Acquire ITM for Up to $2.35 Billion, Radiopharma's Second Mega-Merger in Two Months

Telix – ITM: Telix Pharmaceuticals agreed to acquire ITM Isotope Technologies Munich, a privately held German radioisotope manufacturer, in a deal with an enterprise value of $1.65 billion on a cash-free, debt-free basis. The upfront consideration is paid primarily in Telix shares, 105.8 million shares worth approximately $1.25 billion, plus $302 million in assumed net debt and $96 million in management rollover and transaction expenses. ITM shareholders are also eligible for up to $700 million in additional earn-outs: $250 million tied to FDA approvals across three ITM-11 indications, and $450 million if ITM-11's net sales exceed $150 million in fiscal year 2030, bringing the total potential deal value to $2.35 billion. The deal is expected to close by the end of 2026, pending Telix shareholder approval.

ITM brings a profitable, cash-generative radioisotope manufacturing business spanning lutetium-177, actinium-225, and terbium-161, with 2025 revenue of $273 million growing at a 40% compound annual rate since 2021. It also brings ITM-11 (177Lu-edotreotide), the same product that received an FDA Complete Response Letter in August over manufacturing issues, not efficacy or safety. Telix brings a commercial diagnostics portfolio, Illuccix, Gozellix, and Pixclara, and three pivotal-stage therapeutics. Combined pro forma 2026 revenue is estimated to exceed $1.3 billion.

Telix – Pixclara: The deal lands the same month the FDA approved Telix's Pixclara, a PET imaging agent for glioma, a brain cancer, giving Telix its fourth approved diagnostic product heading into the ITM combination.

Two Lutathera Equivalents Clear FDA in September; Novartis Licenses a $900 Million Radioligand Asset the Same Month

Curium: The FDA approved Curium's BEXLUTRY (lutetium Lu 177 dotatate) through the 505(b)(2) pathway, referencing Novartis's Lutathera, for adults with SSTR-positive gastroenteropancreatic neuroendocrine tumors. The approval follows a June 2026 court ruling that cleared Curium of Novartis's patent-infringement claims over the same product.

Lantheus: Soon after, the FDA granted final approval to Lantheus's BRAVNETSA (lutetium Lu 177 dotatate) through the ANDA pathway, determining it bioequivalent and therapeutically equivalent to Lutathera. The label excludes Lutathera's pediatric indication, which remains under Novartis's separate pediatric exclusivity.

Novartis: Separately, around the same time, Novartis licensed exclusive global rights to a preclinical radioligand therapy asset from Chinese biotech BoomRay, in a deal worth up to $900 million in upfront and milestone payments plus royalties. The specific molecular target has not been disclosed, and Novartis has not described the deal as related to the Curium or Lantheus approvals; the timing is ours to flag, not theirs to explain.

Novartis reported $436 million in Lutathera sales in the first half of 2026, including $225 million in the second quarter alone. Two independent equivalence pathways clearing within the same month, against that revenue base, is the clearest signal yet that radioligand follow-on competition is arriving faster than incumbents had priced in, regardless of whether the BoomRay deal was a direct reaction to it.

Perspective Pairs an Alpha Emitter With Keytruda; a Hypoxia Tracer Earns Breakthrough Status; Norroy Clears Phase III in China

Perspective Therapeutics: Perspective announced a clinical collaboration and supply agreement with Merck to evaluate its targeted alpha-particle therapy, [212Pb]PSV359, combined with Keytruda in FAP-α-positive solid tumors, with the trial focused on non-small cell lung cancer and colorectal cancer. The Phase 1/2a study is sponsored by Perspective; Merck supplies pembrolizumab at no cost, with no milestone payments disclosed.

Juniper Biosciences: The FDA granted Breakthrough Therapy Designation to JBS-003, a hypoxia PET imaging tracer, for use in guiding radiation dose de-escalation in HPV-positive oropharyngeal cancer.

Norroy Bioscience: China's National Medical Products Administration is reported to have cleared initiation of a pivotal Phase III trial of 177Lu-NYM032, a PSMA-targeted radioligand therapy, for metastatic castration-resistant prostate cancer. This is a separate development from Norroy's earlier Phase I/II data and diagnostic-tracer work, but it rests on a single trade-press account with no company release or NMPA notice behind it, so treat the claim itself as less firmly established than the other items in this issue.

Five Financing and Supply Chain Moves Worth Tracking This Month

Ionetix: Ionetix began shipping astatine-211, an alpha-emitting isotope with a 7.2-hour half-life produced by cyclotron irradiation of bismuth-209, to North American preclinical and clinical programs. The company describes itself as a new commercial supplier of At-211; its own SEC filing states there is currently no other commercial supplier in the US, while a competitor has announced plans to enter, so we're not calling it "first" outright.

ABX: German manufacturer ABX (Advanced Biochemical Compounds) acquired TRIMT GmbH, a Saxony-based cyclopeptide radiopharmaceutical startup. TRIMT's pipeline includes three investigational, integrin-targeted candidates: 68Ga-Trivehexin and 68Ga-Triveoctin for PET imaging, and 177Lu-Therahexin for therapy. Deal terms were not disclosed.

Ratio Therapeutics and RayzeBio: The companies entered a research collaboration and license agreement to design, evaluate, and optimize a next-generation radiopharmaceutical candidate against undisclosed cancer targets. Ratio leads the early discovery work and receives an upfront payment plus development, regulatory, and commercial milestones and royalties; RayzeBio takes exclusive worldwide rights to any resulting candidates once that work concludes.

Oncoinvent: Oncoinvent raised NOK 140 million, roughly $13 million, through a private placement at NOK 90 per share, alongside a retail offering of up to the NOK equivalent of EUR 1 million, to fund a more mature Phase 2 interim readout for Radspherin, its radium-224 therapy for peritoneal metastases from ovarian cancer, now expected in March or April 2027. The raise is also meant to extend runway into the second half of 2027 and fund regulatory preparation for a Phase 3 trial.

NorthStar Medical Technologies: NorthStar secured a growth capital facility of up to $185 million, led by Hercules Capital, with $100 million delivered upfront, to scale commercial production of no-carrier-added actinium-225 and expand manufacturing capacity at its Beloit, Wisconsin campus for contract development and manufacturing (CDMO) customers. NorthStar said the facility funds additional suites for early-stage, late-stage, and commercial radiopharmaceutical production, and pointed to an expanded partnership with Convergent Therapeutics on its CONV01-α program as one example of the demand behind the buildout.